SynCore Biotechnology Announces Interim Analysis Results for Novel Pancreatic Cancer Asset, SB05PC (EndoTAG®-1)
SynCore Biotechnology (4192:TT) receives interim analysis results for its [...]
SB05 Pancreatic Cancer Clinical Trial Reaches Conditions to Conduct Interim Analysis
SynCore’s global phase III clinical trial on pancreatic cancer [...]
SB05PC (EndoTAG®-1) Phase III been Approved in China by NMPA
China NMPA Approves SynCore Biotechnology to Conduct Phase III [...]
SynCore Bio Enrolled First Patient In Phase III Trial for SB05 Pancreatic Cancer in Hungary
Taipei, Taiwan, 14 January 2019. SynCore Biotechnology Co. (4192:TT) announces [...]
SynCore Bio Doses First Patient In Phase III Trial for SB05 Pancreatic Cancer in South Korea
Taipei, Taiwan, 25 December 2018. SynCore Biotechnology Co. (4192:TT) [...]
SB05 PC is Approved to Conduct Phase III Clinical Trial for Pancreatic Cancer in Israel
SB05 (EndoTAG®-1) is approved to conduct [...]
SB05 PC is Approved to Conduct Phase III Clinical Trial for Pancreatic Cancer in Russia
SB05 (EndoTAG®-1) is approved to conduct Phase III clinical trial [...]
SynCore Biotechnology has Received the Approval to Conduct SB05 PC for Phase III Clinical Trial in South Korea
SB05 (EndoTAG®-1) is approved to conduct Phase III clinical trial in [...]
SB05 PC for Pancreatic Cancer is Approved to implement Phase III Clinical Trial in Hungary
SynCore Biotechnology has received the approval from OGYEI to [...]
SynCore Bio Signs Agreement with British Company Epipole to Distribute Eye Disease Diagnosis Fundus Cameras in Taiwan
SynCore Biotechnology Co. Ltd. (4192) signed an international contract [...]